Jeffrey R Strawn1, Jeffrey A Mills2, Beau A Sauley2, Jeffrey A Welge3. 1. University of Cincinnati College of Medicine; Cincinnati Children's Hospital Medical Center. Electronic address: strawnjr@uc.edu. 2. Carl H. Lindner College of Business, University of Cincinnati. 3. University of Cincinnati College of Medicine.
Abstract
OBJECTIVE: To determine the trajectory and magnitude of antidepressant response as well as the effect of antidepressant class and dose on symptomatic improvement in pediatric anxiety disorders. METHOD: Weekly symptom severity data were extracted from randomized, parallel group, placebo-controlled trials of selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs) in pediatric anxiety disorders. Treatment response was modeled for the standardized change in continuous measures of anxiety using Bayesian updating. Posterior distributions for each study served as informative conjugate prior to distributions update subsequent study posteriors. Change in symptom severity was evaluated as a function of time, class and, for SSRIs, standardized dose. RESULTS: Data from 9 trials (SSRIs: n = 5; SNRIs, n = 4) evaluating 7 medications in 1,673 youth were included. In the logarithmic model of treatment response, statistically, but not clinically, significant treatment effects emerged within 2 weeks of beginning treatment (standardized medication-placebo difference = -0.054, credible interval [CI] = -0.076 to -0.032, p = .005, approximate Cohen's d ≤ 0.2) and by week 6, clinically significant differences emerged (standardized medication-placebo difference = -0.120, CI = -0.142 to -0.097, p = .001, approximate Cohen's d = 0.44). Compared to SNRIs, SSRIs resulted in significantly greater improvement by the second week of treatment (p = .0268), and this advantage remained statistically significant through week 12 (all p values <.03). Improvement occurred earlier with high-dose SSRI treatment (week 2, p = .002) compared to low-dose treatment (week 10, p = .025), but SSRI dose did not have an impact on overall response trajectory (p > .18 for weeks 1-12). CONCLUSIONS: In pediatric patients with generalized, separation, and/or social anxiety disorders, antidepressant-related improvement occurred early in the course of treatment, and SSRIs were associated with more rapid and greater improvement compared to SNRIs.
OBJECTIVE: To determine the trajectory and magnitude of antidepressant response as well as the effect of antidepressant class and dose on symptomatic improvement in pediatric anxiety disorders. METHOD: Weekly symptom severity data were extracted from randomized, parallel group, placebo-controlled trials of selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs) in pediatric anxiety disorders. Treatment response was modeled for the standardized change in continuous measures of anxiety using Bayesian updating. Posterior distributions for each study served as informative conjugate prior to distributions update subsequent study posteriors. Change in symptom severity was evaluated as a function of time, class and, for SSRIs, standardized dose. RESULTS: Data from 9 trials (SSRIs: n = 5; SNRIs, n = 4) evaluating 7 medications in 1,673 youth were included. In the logarithmic model of treatment response, statistically, but not clinically, significant treatment effects emerged within 2 weeks of beginning treatment (standardized medication-placebo difference = -0.054, credible interval [CI] = -0.076 to -0.032, p = .005, approximate Cohen's d ≤ 0.2) and by week 6, clinically significant differences emerged (standardized medication-placebo difference = -0.120, CI = -0.142 to -0.097, p = .001, approximate Cohen's d = 0.44). Compared to SNRIs, SSRIs resulted in significantly greater improvement by the second week of treatment (p = .0268), and this advantage remained statistically significant through week 12 (all p values <.03). Improvement occurred earlier with high-dose SSRI treatment (week 2, p = .002) compared to low-dose treatment (week 10, p = .025), but SSRI dose did not have an impact on overall response trajectory (p > .18 for weeks 1-12). CONCLUSIONS: In pediatric patients with generalized, separation, and/or social anxiety disorders, antidepressant-related improvement occurred early in the course of treatment, and SSRIs were associated with more rapid and greater improvement compared to SNRIs.
Authors: Anna M Wehry; Katja Beesdo-Baum; Meghann M Hennelly; Sucheta D Connolly; Jeffrey R Strawn Journal: Curr Psychiatry Rep Date: 2015-07 Impact factor: 5.285
Authors: Philip C Kendall; Scott N Compton; John T Walkup; Boris Birmaher; Anne Marie Albano; Joel Sherrill; Golda Ginsburg; Moira Rynn; James McCracken; Elizabeth Gosch; Courtney Keeton; Lindsey Bergman; Dara Sakolsky; Cindy Suveg; Satish Iyengar; John March; John Piacentini Journal: J Anxiety Disord Date: 2010-02-06
Authors: Dara J Sakolsky; James M Perel; Graham J Emslie; Gregory N Clarke; Karen Dineen Wagner; Benedetto Vitiello; Martin B Keller; Boris Birmaher; Joan Rosenbaum Asarnow; Neal D Ryan; James T McCracken; Michael J Strober; Satish Iyengar; Giovanna Porta; David A Brent Journal: J Clin Psychopharmacol Date: 2011-02 Impact factor: 3.153
Authors: Cosima Locher; Helen Koechlin; Sean R Zion; Christoph Werner; Daniel S Pine; Irving Kirsch; Ronald C Kessler; Joe Kossowsky Journal: JAMA Psychiatry Date: 2017-10-01 Impact factor: 21.596
Authors: David A Brent; Graham J Emslie; Greg N Clarke; Joan Asarnow; Anthony Spirito; Louise Ritz; Benedetto Vitiello; Satish Iyengar; Boris Birmaher; Neal D Ryan; Jamie Zelazny; Matthew Onorato; Betsy Kennard; Taryn L Mayes; Lynn L Debar; James T McCracken; Michael Strober; Robert Suddath; Henrietta Leonard; Giovanna Porta; Martin B Keller Journal: Am J Psychiatry Date: 2009-02-17 Impact factor: 18.112
Authors: Scott N Compton; John T Walkup; Anne Marie Albano; John C Piacentini; Boris Birmaher; Joel T Sherrill; Golda S Ginsburg; Moira A Rynn; James T McCracken; Bruce D Waslick; Satish Iyengar; Phillip C Kendall; John S March Journal: Child Adolesc Psychiatry Ment Health Date: 2010-01-05 Impact factor: 3.033
Authors: Jeffrey R Strawn; Laura Geracioti; Neil Rajdev; Kelly Clemenza; Amir Levine Journal: Expert Opin Pharmacother Date: 2018-07 Impact factor: 3.889
Authors: Robert Peter Biney; Charles Kwaku Benneh; Donatus Wewura Adongo; Elvis Ofori Ameyaw; Eric Woode Journal: Psychopharmacology (Berl) Date: 2021-04-10 Impact factor: 4.530
Authors: Bradley S Peterson; Amy E West; John R Weisz; Wendy J Mack; Michele D Kipke; Robert L Findling; Brian S Mittman; Ravi Bansal; Steven Piantadosi; Glenn Takata; Corinna Koebnick; Ceth Ashen; Christopher Snowdy; Marie Poulsen; Bhavana Kumar Arora; Courtney M Allem; Marisa Perez; Stephanie N Marcy; Bradley O Hudson; Stephanie H Chan; Robin Weersing Journal: BMC Psychiatry Date: 2021-06-30 Impact factor: 3.630